Efforts to make customized medicines at scale have hit commercial and regulatory roadblocks. Julia Vintarello is trying again.
Adobe
By Andrew Joseph
May 1, 2026
Europe Correspondent
Andrew Joseph
Emilia McLaughlin’s Kyron.bio is reshaping drug manufacturing—and breaking barriers as a solo female biotech founder in Europe.
As its ultra-rare disease med Miplyffa strengthens its foothold in the U.S., Zevra Therapeutics’ CEO believes the launch has the…
Lyora Therapeutics launches with $2.5M in pre-seed funding to revive stalled eye gene therapy programs from Editas and Biogen,…
Medicine is undergoing a profound transformation by shifting focus from populations to individual patients. A novel custom drug…
Mary Catchpole, 19, receives ‘life-changing’ treatment for immune condition after NHS approval
Grace Science CEO Matt Wilsey says FDA demands could kill its gene therapy for the rare and fatal NGLY1 deficiency by September…
